Why AVITA Medical Inc (RCEL) Stock Is Rising
As of 2026-11-12, AVITA Medical Inc (RCEL) has a next-year EPS growth estimate of 59.45%. Featured in 5 EPS revision reports, most recently on 2026-08-18.
Why RCEL Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised AVITA Medical Inc's next-year EPS growth estimate from 59.31% to 60.59% on 2026-11-06.
- ·Current-Year Growth: Projected at 47.95%, supporting the forward estimate revision.
News Context
The primary structural driver appears to be the August 19, 2026 analyst increase in next-year EPS growth estimates from 53.06% to 59.31%. That revision is plausibly supported by Q2 2026 results, raised 2026 revenue guidance, expected fourth-quarter cash flow breakeven, and positive PermeaDerm study results showing a 70% economic advantage over allograft. Subsequent headlines about record quarterly performance and the shares’ surge suggest the move has continued beyond the initial estimate revision.
Generated 2026-10-23 · news as of 2026-10-23
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Devices
- EPS growth next year
- 59.45%
- EPS growth this year
- 47.95%
- EPS next quarter (est)
- -$0.15
- Last price
- $16.20
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 59.45% | 47.95% | -$0.15 | $16.20 |
| 2026-11-11 | 57.80% | 47.71% | -$0.15 | $17.30 |
| 2026-11-10 | 58.43% | 46.49% | -$0.16 | $17.65 |
| 2026-11-09 | 58.43% | 46.49% | -$0.16 | $17.12 |
| 2026-11-07 | 60.59% | 47.00% | -$0.16 | $16.59 |
| 2026-11-06 | 60.59% | 47.00% | -$0.16 | $16.59 |
| 2026-11-05 | 59.31% | 45.66% | -$0.24 | $15.68 |
| 2026-11-04 | 59.31% | 45.66% | -$0.24 | $16.32 |
| 2026-11-03 | 59.31% | 45.66% | -$0.24 | $15.33 |
| 2026-11-02 | 59.31% | 45.66% | -$0.24 | $15.41 |
| 2026-10-31 | 59.31% | 45.66% | -$0.24 | $15.65 |
| 2026-10-30 | 59.31% | 45.66% | -$0.24 | $15.65 |
| 2026-10-29 | 59.31% | 45.66% | -$0.24 | $16.71 |
| 2026-10-28 | 59.31% | 45.66% | -$0.24 | $16.50 |
| 2026-10-27 | 59.31% | 45.66% | -$0.24 | $16.08 |
| 2026-10-26 | 59.31% | 45.66% | -$0.24 | $15.18 |
| 2026-10-23 | 59.31% | 45.66% | -$0.24 | $15.51 |
| 2026-10-22 | 59.31% | 45.66% | -$0.24 | $15.42 |
| 2026-10-21 | 59.31% | 45.66% | -$0.24 | $15.29 |
| 2026-10-20 | 59.31% | 45.66% | -$0.24 | $13.80 |
| 2026-10-19 | 59.31% | 45.66% | -$0.24 | $13.14 |
| 2026-10-16 | 59.31% | 45.66% | -$0.24 | $13.04 |
| 2026-10-15 | 59.31% | 45.66% | -$0.24 | $13.41 |
| 2026-10-14 | 59.31% | 45.66% | -$0.24 | $13.10 |
| 2026-10-13 | 59.31% | 45.66% | -$0.24 | $13.36 |
| 2026-10-12 | 59.31% | 45.66% | -$0.24 | $13.37 |
| 2026-10-11 | 59.35% | 45.64% | -$0.24 | $13.21 |
| 2026-10-10 | 59.35% | 45.64% | -$0.24 | $13.21 |
| 2026-10-09 | 59.35% | 45.64% | -$0.24 | $13.21 |
| 2026-10-08 | 59.35% | 45.64% | -$0.24 | $13.33 |
Reports Featuring RCEL
- 2026-08-18
Sandisk Surges 32.7% After EPS Revision; ARGX, RCEL Rally
- 2026-07-22
Forward Air (FWRD) surges 25.6% as EPS revision sparks rally
- 2026-07-21
FWRD Leads EPS Revision Surge with 26.7% Gain; AEHR, RCEL Follow
- 2026-07-20
RCEL leads with 27.9% gain on EPS revision; other healthcare stocks follow
- 2026-07-17
RCEL surges 26.9% on EPS revision; COTY, RH, BILL, CVI also gain
Recent News
- AVITA Medical to Host Investor Webinar BriefingGlobeNewswire
- AVITA Medical's 53% Growth And Second Guidance Raise Remove Going-Concern Doubt, But A Flat Q4 Guide Tests A Stock Up 171%Earnings Whispers
- AVITA Medical Reports Third Quarter ResultsGlobeNewswire
- AVITA Medical Announces Positive PermeaDerm Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical OutcomesGlobeNewswire
- AVITA Medical to Host Investor Webinar BriefingGlobeNewswire
- AVITA Medical Announces Participation at Canaccord Genuity Growth ConferenceGlobeNewswire
- AVITA Medical Announces Participation at Canaccord Genuity Growth ConferenceGlobeNewswire
- AVITA Medical, Inc. Q2 2026 Earnings Call SummaryMoby
- Avita Medical Shares Surge After Record Second-Quarter PerformanceInvestorsHub
- AVITA Medical Inc (AVHHL) (Q2 2026) Earnings Call Highlights: Revenue Surges 18% to $21. ...GuruFocus.com
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did AVITA Medical Inc (RCEL) stock go up recently?▾
AVITA Medical Inc (RCEL) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 59.31% to 60.59% on 2026-11-06. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is AVITA Medical Inc's next-year EPS growth estimate?▾
As of 2026-11-12, AVITA Medical Inc (RCEL) has a next-year EPS growth estimate of 59.45%, based on analyst consensus.
When was the latest EPS estimate revision for RCEL?▾
The most recent revision occurred on 2026-11-12, when analysts adjusted the next-year EPS growth estimate from 57.80% to 59.45%.
What sector and industry does AVITA Medical Inc belong to?▾
AVITA Medical Inc operates in the Healthcare sector, specifically the Medical Devices industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RCEL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. AVITA Medical Inc (RCEL) appears here because it was detected by our daily top-EPS-revision-performer screen.